- Home
- AKTX vs PMN Comparison
AKTX vs PMN Comparison
Compare AKTX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- PMN
- Stock Information
- Founded
- AKTX N/A
- PMN 2004
- Country
- AKTX United States
- PMN Canada
- Employees
- AKTX N/A
- PMN N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- AKTX Health Care
- PMN Health Care
- Exchange
- AKTX Nasdaq
- PMN Nasdaq
- Market Cap
- AKTX 41.8M
- PMN 17.0M
- IPO Year
- AKTX N/A
- PMN N/A
- Fundamental
- Price
- AKTX $1.17
- PMN $0.45
- Analyst Decision
- AKTX
- PMN Strong Buy
- Analyst Count
- AKTX 0
- PMN 2
- Target Price
- AKTX N/A
- PMN $4.50
- AVG Volume (30 Days)
- AKTX 27.5K
- PMN 50.5K
- Earning Date
- AKTX 08-18-2025
- PMN 08-07-2025
- Dividend Yield
- AKTX N/A
- PMN N/A
- EPS Growth
- AKTX N/A
- PMN N/A
- EPS
- AKTX N/A
- PMN N/A
- Revenue
- AKTX N/A
- PMN N/A
- Revenue This Year
- AKTX N/A
- PMN N/A
- Revenue Next Year
- AKTX N/A
- PMN N/A
- P/E Ratio
- AKTX N/A
- PMN N/A
- Revenue Growth
- AKTX N/A
- PMN N/A
- 52 Week Low
- AKTX $0.85
- PMN $0.43
- 52 Week High
- AKTX $4.40
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- AKTX 45.49
- PMN 33.76
- Support Level
- AKTX $1.10
- PMN $0.48
- Resistance Level
- AKTX $1.18
- PMN $0.50
- Average True Range (ATR)
- AKTX 0.07
- PMN 0.03
- MACD
- AKTX 0.00
- PMN -0.00
- Stochastic Oscillator
- AKTX 53.25
- PMN 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.